These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28634589)

  • 1. HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.
    Ravindranath MH
    J Immunol Res; 2017; 2017():3475926. PubMed ID: 28634589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg.
    Ravindranath MH; Terasaki PI; Pham T; Jucaud V; Kawakita S
    Clin Exp Immunol; 2014 Oct; 178(1):154-77. PubMed ID: 24889882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HLA-E monoclonal antibodies reacting with HLA-la and lb alleles like IVIg as potential IVIg-immunomimetics: an evolving therapeutic concept.
    Ravindranath MH; Zhu D; Pham T; Jucaud V; Hopfield J; Kawakita S; Terasaki PI
    Clin Transpl; 2013; ():293-305. PubMed ID: 25095521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.
    Zhu D; Ravindranath MH; Terasaki PI; Miyazaki T; Pham T; Jucaud V
    Clin Exp Immunol; 2014 Aug; 177(2):464-77. PubMed ID: 24611451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles.
    Ravindranath MH; Terasaki PI; Pham T; Jucaud V; Kawakita S
    Blood; 2013 Mar; 121(11):2013-28. PubMed ID: 23305735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg.
    Ravindranath MH; Hilali FE; Filippone EJ
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34205517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells.
    Tjon AS; Tha-In T; Metselaar HJ; van Gent R; van der Laan LJ; Groothuismink ZM; te Boekhorst PA; van Hagen PM; Kwekkeboom J
    Clin Exp Immunol; 2013 Aug; 173(2):259-67. PubMed ID: 23607448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel cross-reactive anti-idiotype antibodies with properties close to the human intravenous immunoglobulin (IVIg).
    Macias A; Arce S; Leon J; Mustelier G; Bombino G; Domarco A; Perez R; Lage A
    Hybridoma; 1999 Jun; 18(3):263-72. PubMed ID: 10475241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells.
    Tha-In T; Metselaar HJ; Bushell AR; Kwekkeboom J; Wood KJ
    Transplantation; 2010 Jun; 89(12):1446-55. PubMed ID: 20463648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nature and Clonality of the Fluoresceinated Secondary Antibody in Luminex Multiplex Bead Assays Are Critical Factors for Reliable Monitoring of Serum HLA Antibody Levels in Patients for Donor Organ Selection, Desensitization Therapy, and Assessment of the Risk for Graft Loss.
    Ravindranath MH; Jucaud V; Banuelos N; Everly MJ; Cai J; Nguyen A; Terasaki PI
    J Immunol; 2017 Jun; 198(11):4524-4538. PubMed ID: 28476933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation.
    Ferrari-Lacraz S; Aubert V; Buhler L; Pascual M; Andresen I; Binet I; Martin PY; Villard J
    Swiss Med Wkly; 2006 Oct; 136(43-44):696-702. PubMed ID: 17183432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Natural Killer and CD8
    Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients.
    Pilon C; Bigot J; Grondin C; Thiolat A; Lang P; Cohen JL; Grimbert P; Matignon M
    Front Immunol; 2020; 11():34. PubMed ID: 32038663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera.
    Ravindranath MH; Kaneku H; El-Awar N; Morales-Buenrostro LE; Terasaki PI
    J Immunol; 2010 Aug; 185(3):1935-48. PubMed ID: 20610644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients.
    John R; Lietz K; Burke E; Ankersmit J; Mancini D; Suciu-Foca N; Edwards N; Rose E; Oz M; Itescu S
    Circulation; 1999 Nov; 100(19 Suppl):II229-35. PubMed ID: 10567309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of allogeneic cells on the human T and B cell repertoire.
    van Rood JJ; Claas FH
    Science; 1990 Jun; 248(4961):1388-93. PubMed ID: 1972596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-year experience with treatment of early donor-specific anti-HLA antibodies in pediatric lung transplantation using a human immunoglobulin-based protocol.
    Ius F; Müller C; Sommer W; Verboom M; Hallensleben M; Salman J; Siemeni T; Kühn C; Avsar M; Bobylev D; Poyanmehr R; Erdfelder C; Böthig D; Carlens J; Bayir L; Hansen G; Blasczyk R; Falk C; Tecklenburg A; Haverich A; Tudorache I; Schwerk N; Warnecke G
    Pediatr Pulmonol; 2020 Mar; 55(3):754-764. PubMed ID: 31909902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of IVIG administration on complement activation and HLA antibody levels.
    Machimoto T; Guerra G; Burke G; Fricker FJ; Colona J; Ruiz P; Meier-Kriesche HU; Scornik J
    Transpl Int; 2010 Oct; 23(10):1015-22. PubMed ID: 20412537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.